In 2013, the journal Science considered immunotherapy to be the scientific breakthrough of the year, and one of the disciplines in which it has undoubtedly advanced the most is NSCLC as a result of the use of PD 1 and CTLA-4 immune checkpoint inhibitors (ICIs) [6]. Here, RPL17 is linked to non-small cell lung carcinoma.